Loading...
 
Toggle Health Problems and D

Many Chronic Health Diseases and Infections can controlled by 40 ng of Vitamin D – Aug 2023

Controlling Chronic Diseases and Acute Infections with Vitamin D Sufficiency

Nutrients 2023, 15(16), 3623; https://doi.org/10.3390/nu15163623
by Sunil J. Wimalawansa, Dept of Medicine, CardioMetabolic & Endocrine Institute, North Brunswick, NJ 08902, USA

Table of Contents
Image

Image

Image

Image
Apart from developmental disabilities, the prevalence of chronic diseases increases with age especially in those with co-morbidities: vitamin D deficiency plays a major role in it. Whether vitamin D deficiency initiates and/or aggravates chronic diseases or vice versa is unclear. It adversely affects all body systems but can be eliminated using proper doses of vitamin D supplementation and/or safe daily sun exposure. Maintaining the population serum 25(OH)D concentration above 40 ng/mL (i.e., sufficiency) ensures a sound immune system, minimizing symptomatic diseases and reducing infections and the prevalence of chronic diseases. This is the most cost-effective way to keep a population healthy and reduce healthcare costs. Vitamin D facilitates physiological functions, overcoming pathologies such as chronic inflammation and oxidative stress and maintaining broader immune functions. These are vital to overcoming chronic diseases and infections. Therefore, in addition to following essential public health and nutritional guidance, maintaining vitamin D sufficiency should be an integral part of better health, preventing acute and chronic diseases and minimize their complications. Those with severe vitamin D deficiency have the highest burdens of co-morbidities and are more vulnerable to developing complications and untimely deaths. Vitamin D adequacy improves innate and adaptive immune systems. It controls excessive inflammation and oxidative stress, generates antimicrobial peptides, and neutralizes antibodies via immune cells. Consequently, vitamin D sufficiency reduces infections and associated complications and deaths. Maintaining vitamin D sufficiency reduces chronic disease burden, illnesses, hospitalizations, and all-cause mortality. Vulnerable communities, such as ethnic minorities living in temperate countries, older people, those with co-morbidities, routine night workers, and institutionalized persons, have the highest prevalence of vitamin D deficiency—they would significantly benefit from vitamin D and targeted micronutrient supplementation. At least now, health departments, authorities, and health insurance companies should start assessing, prioritizing, and encouraging this economical, non-prescription, safe micronutrient to prevent and treat acute and chronic diseases. This approach will significantly reduce morbidity, mortality, and healthcare costs and ensure healthy aging.
 Download the PDF from VitaminDWiki

168 References
  1. Zdrenghea, M.T.; Makrinioti, H.; Bagacean, C.; Bush, A.; Johnston, S.L.; Stanciu, L.A. Vitamin D modulation of innate immune responses to respiratory viral infections. Rev. Med. Virol. 2017, 27, e1909. [CrossRef]
  2. Gotelli, E.; Soldano, S.; Hysa, E.; Paolino, S.; Campitiello, R.; Pizzorni, C.; Sulli, A.; Smith, V.; Cutolo, M. Vitamin D and COVID-19: Narrative Review after 3 Years of Pandemic. Nutrients 2022,14, 4907. [CrossRef] [PubMed]
  3. Hollis, B.W.; Marshall, D.T.; Savage, S.J.; Garrett-Mayer, E.; Kindy, M.S.S.; Gattoni-Celli, S. Vitamin D3 supplementation, low-risk prostate cancer, and health disparities. J. Steroid Biochem. Mol. Biol. 2013,136, 233-237. [CrossRef] [PubMed]
  4. Xiaoyu, Z.; Payal, B.; Melissa, O.; Zanello, L.P. 1alpha,25(OH)2-vitamin D3 membrane-initiated calcium signaling modulates exocytosis and cell survival. J. Steroid Biochem. Mol. Biol. 2007,103, 457-461. [CrossRef]
  5. Liang, F.; Liu, C.; Li, L.; Guo, Y.; Bai, L. Effects of gastrin on rat intestinal epithelial 1,25(OH)2D3-membrane associated rapid response steroid binding protein. Nan Fang Yi Ke Da Xue Xue Bao 2013, 33, 990-993. [PubMed]
  6. Vieth, R. Why the optimal requirement for Vitamin D3 is probably much higher than what is officially recommended for adults. J. Steroid Biochem. Mol. Biol. 2004, 89-90, 575-579. [CrossRef]
  7. Wimalawansa, S.J. Vitamin D in the new millennium. Curr. Osteoporos. Rep. 2012,10, 4-15. [CrossRef]
  8. Bouillon, R. Genetic and racial differences in the vitamin D endocrine system. Endocrinol. Metab. Clin. N. Am. 2017, 46,1119-1135. [CrossRef]
  9. Holick, M.F.; Chen, T.C.; Lu, Z.; Sauter, E. Vitamin D and skin physiology: A D-lightful story. J. Bone Miner. Res. 2007, 22 (Suppl. S2), V28-V33. [CrossRef]
  10. Engelsen, O. The relationship between ultraviolet radiation exposure and vitamin D status. Nutrients 2010, 2, 482-495. [CrossRef]
  11. Webb, A.R.; Alghamdi, R.; Kift, R.; Rhodes, L.E. 100 Years of Vitamin D: Dose-response for change in 25-hydroxyvitamin D after UV exposure: Outcome of a systematic review. Endocr. Connect. 2021,10, R248-R266. [CrossRef] [PubMed]
  12. Wimalawansa, S.J. Public health interventions for chronic diseases: Cost-benefit modelizations for eradicating chronic kidney disease of multifactorial origin (CKDmfo/CKDu) from tropical countries. Heliyon 2019, 5, e02309. [CrossRef] [PubMed]
  13. Wimalawansa, S.J. Biology of vitamin D. J. Steroids Horm Sci. 2019,10, 2. [CrossRef]
  14. Adams, J.S.; Clemens, T.L.; Parrish, J.A.; Holick, M.F. Vitamin-D synthesis and metabolism after ultraviolet irradiation of normal and vitamin-D-deficient subjects. N. Engl. J. Med. 1982, 306, 722-725. [CrossRef]
  15. Vieth, R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am. J. Clin. Nutr. 1999, 69, 842-856. [CrossRef]
  16. Hollis, B.W.; Johnson, D.; Hulsey, T.C.; Ebeling, M.; Wagner, C.L. Vitamin D supplementation during pregnancy: Double-blind, randomized clinical trial of safety and effectiveness. J. Bone Miner. Res. 2011, 26, 2341-2357. [CrossRef]
  17. Nykjaer, A.; Dragun, D.; Walther, D.; Vorum, H.; Jacobsen, C.; Herz, J.; Melsen, F.; Christensen, E.I.; Willnow, T.E. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999, 96, 507-515. [CrossRef]
  18. Aatsinki, S.M.; Elkhwanky, M.S.; Kummu, O.; Karpale, M.; Buler, M.; Viitala, P.; Rinne, V.; Mutikainen, M.; Tavi, P.; Franko, A.; et al. Fasting-Induced Transcription Factors Repress Vitamin D Bioactivation, a Mechanism for Vitamin D Deficiency in Diabetes. Diabetes 2019, 68, 918-931. [CrossRef]
  19. Elkhwanky, M.S.; Kummu, O.; Piltonen, T.T.; Laru, J.; Morin-Papunen, L.; Mutikainen, M.; Tavi, P.; Hakkola, J. Obesity represses CYP2R1, the vitamin D 25-Hydroxylase, in the liver and extrahepatic tissues. JBMR Plus 2020, 4, e10397. [CrossRef]
  20. Haddad, J.G.; Hillman, L.; Rojanasathit, S. Human serum binding capacity and affinity for 25-hydroxyergocalciferol and 25-hydroxycholecalciferol. J. Clin. Endocrinol. Metab. 1976, 43,86-91. [CrossRef]
  21. Keenan, M.J.; Holmes, R.P. The uptake and metabolism of 25-hydroxyvitamin D3 and vitamin D binding protein by cultured porcine kidney cells (LLC-PK1). Int. J. Biochem. 1991,23,1225-1230. [CrossRef]
  22. Kissmeyer, A.; Mathiasen, I.S.; Latini, S.; Binderup, L. Pharmacokinetic studies of vitamin D analogues: Relationship to vitamin D binding protein (DBP). Endocrine 1995, 3, 263-266. [CrossRef] [PubMed]
  23. Vieth, R.; Kessler, M.J.; Pritzker, K.P. Species differences in the binding kinetics of 25-hydroxyvitamin D3 to vitamin D binding protein. Can. J. Physiol. Pharmacol. 1990, 68,1368-1371. [CrossRef] [PubMed]
  24. Wimalawansa, S.J. Non-musculoskeletal benefits of vitamin D. J. Steroid Biochem. Mol. Biol. 2018,175, 60-81. [CrossRef] [PubMed]
  25. Zhang, Q.; Wang, M.; Han, C.; Wen, Z.; Meng, X.; Qi, D.; Wang, N.; Du, H.; Wang, J.; Lu, L.; et al. Intraduodenal Delivery of Exosome-Loaded SARS-CoV-2 RBD mRNA Induces a Neutralizing Antibody Response in Mice. Vaccines 2023,11, 673. [CrossRef]
  26. Jiang, Y.; Chen, L.; Taylor, R.N.; Li, C.; Zhou, X. Physiological and pathological implications of retinoid action in the endometrium. J. Endocrinol. 2018, 236, R169-R188. [CrossRef]
  27. Keane, K.N.; Cruzat, V.F.; Calton, E.K.; Hart, P.H.; Soares, M.J.; Newsholme, P.; Yovich, J.L. Molecular actions of vitamin D in reproductive cell biology. Reproduction 2017,153, R29-R42. [CrossRef]
  28. Holick, M.F. The cutaneous photosynthesis of previtamin D3: A unique photoendocrine system. J. Investig. Dermatol. 1981, 77, 51-58. [CrossRef]
  29. Haddad, J.G.; Matsuoka, L.Y.; Hollis, B.W.; Hu, Y.Z.; Wortsman, J. Human plasma transport of vitamin D after its endogenous synthesis. J. Clin. Investig. 1993, 91, 2552-2555. [CrossRef]
  30. Ponchon, G.; Kennan, A.L.; DeLuca, H.F. "Activation" of vitamin D by the liver. J. Clin. Investig. 1969, 48, 2032-2037. [CrossRef]
  31. Hosseinpour, F.; Wikvall, K. Porcine microsomal vitamin D(3) 25-hydroxylase (CYP2D25). Catalytic properties, tissue distribution, and comparison with human CYP2D6. J. Biol. Chem. 2000,275, 34650-34655. [CrossRef] [PubMed]
  32. Flanagan, J.N.; Young, M.V.; Persons, K.S.; Wang, L.; Mathieu, J.S.; Whitlatch, L.W.; Holick, M.F.; Chen, T.C. Vitamin D metabolism in human prostate cells: Implications for prostate cancer chemoprevention by vitamin D. Anticancer Res. 2006, 26, 2567-2572. [PubMed]
  33. Zhu, P.; Ren, M.; Yang, C.; Hu, Y.X.; Ran, J.M.; Yan, L. Involvement of RAGE, MAPK and NF-kappaB pathways in AGEs-induced MMP-9 activation in HaCaT keratinocytes. Exp. Dermatol. 2012, 21,123-129. [CrossRef]
  34. McBrearty, N.; Cho, C.; Chen, J.; Zahedi, F.; Peck, A.R.; Radaelli, E.; Assenmacher, C.A.; Pavlak, C.; Devine, A.; Yu, P.; et al. Tumor-Suppressive and Immune-Stimulating Roles of Cholesterol 25-hydroxylase in Pancreatic Cancer Cells. Mol. Cancer Res. 2023, 21, 228-239. [CrossRef]
  35. Karlgren, M.; Miura, S.; Ingelman-Sundberg, M. Novel extrahepatic cytochrome P450s. Toxicol. Appl. Pharmacol. 2005, 207, 57-61. [CrossRef]
  36. Smith, J.E.; Goodman, D.S. The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma. J. Clin. Investig. 1971, 50, 2159-2167. [CrossRef] [PubMed]
  37. Lo, C.W.; Paris, P.W.; Clemens, T.L.; Nolan, J.; Holick, M.F. Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes. Am. J. Clin. Nutr. 1985, 42, 644-649. [CrossRef]
  38. Heaney, R.P.; Recker, R.R.; Grote, J.; Horst, R.L.; Armas, L.A. Vitamin D(3) is more potent than vitamin D(2) in humans. J. Clin. Endocrinol. Metab. 2011, 96, E447-E452. [CrossRef]
  39. Mangin, M.; Sinha, R.; Fincher, K. Inflammation and vitamin D: The infection connection. Inflamm. Res. 2014, 63, 803-819. [CrossRef]
  40. Chung, M.K.; Karnik, S.; Saef, J.; Bergmann, C.; Barnard, J.; Lederman, M.M.; Tilton, J.; Cheng, F.; Harding, C.V.; Young, J.B.; et al. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. EBioMedicine 2020, 58, 102907. [CrossRef]
  41. Wimalawansa, S.J. Physiological basis for using vitamin D to improve health. Biomedicines 2023,11,1542. [CrossRef] [PubMed]
  42. Arai, Y.; Kanda, E.; Iimori, S.; Naito, S.; Noda, Y.; Kawasaki, T.; Sato, H.; Ando, R.; Sasaki, S.; Sohara, E.; et al. The use of vitamin D analogs is independently associated with the favorable renal prognosis in chronic kidney disease stages 4-5: The CKD-ROUTE study. Clin. Exp. Nephrol. 2017, 21, 481-487. [CrossRef] [PubMed]
  43. Oh, T.R.; Kim, C.S.; Bae, E.H.; Ma, S.K.K.; Han, S.H.; Sung, S.A.; Lee, K.; Oh, K.H.; Ahn, C.; Kim, S.W.; et al. Association between vitamin D deficiency and health-related quality of life in patients with chronic kidney disease from the KNOW-CKD study. PLoS ONE 2017,12, e0174282. [CrossRef]
  44. Zittermann, A.; Iodice, S.; Pilz, S.; Grant, W.B.; Bagnardi, V.; Gandini, S. Vitamin D deficiency and mortality risk in the general population: A meta-analysis of prospective cohort studies. Am. J. Clin. Nutr. 2012, 95, 91-100. [CrossRef] [PubMed]
  45. Jean, G.; Souberbielle, J.C.; Chazot, C. Vitamin D in Chronic Kidney Disease and Dialysis Patients. Nutrients 2017, 9, 328. [CrossRef] [PubMed]
  46. Waziri, B.; Duarte, R.; Naicker, S. Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives. Int. J. Nephrol. Renovasc. Dis. 2019,12, 263-276. [CrossRef] [PubMed]
  47. Urena-Torres, P.; Metzger, M.; Haymann, J.P.; Karras, A.; Boffa, J.J.; Flamant, M.; Vrtovsnik, F.; Gauci, C.; Froissart, M.; Houillier, P.; et al. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. Am. J. Kidney Dis. 2011, 58, 544-553. [CrossRef]
  48. Kanai, G.; Fukagawa, M. CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Gene therapy for secondary hyperparathyroidism. Clin. Calcium 2010, 20,1052-1059.
  49. Zelnick, L.R.; de Boer, I.H.; Kestenbaum, B.R.; Chonchol, M.; Kendrick, J. Comparative Effects of Cholecalciferol and Calcitriol on Circulating Markers of CKD Mineral Bone Disorder: A Randomized Clinical Trial. Clin. J. Am. Soc. Nephrol. 2018,13, 927-928. [CrossRef]
  50. Bansal, N.; Katz, R.; Appel, L.; Denburg, M.; Feldman, H.; Go, A.S.; He, J.; Hoofnagle, A.; Isakova, T.; Kestenbaum, B.; et al. Vitamin D Metabolic Ratio and Risks of Death and CKD Progression. Kidney Int. Rep. 2019, 4,1598-1607. [CrossRef]
  51. Durazo-Arvizu, R.A.; Dawson-Hughes, B.; Kramer, H.; Cao, G.; Merkel, J.; Coates, P.M.; Sempos, C.T. The reverse J-shaped association between serum total 25-hydroxyvitamin D concentration and all-cause mortality: The impact of assay standardization. Am. J. Epidemiol. 2017,185, 720-726. [CrossRef] [PubMed]
  52. Durup, D.; Jorgensen, H.L.; Christensen, J.; Schwarz, P.; Heegaard, A.M.; Lind, B. A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: The CopD study. J. Clin. Endocrinol. Metab. 2012, 97, 2644-2652. [CrossRef] [PubMed]
  53. Grant, W.B. Letter to the Editor: The J-shaped 25-hydroxyvitamin D concentration-cardiovascular disease mortality relation is very likely due to starting vitamin D supplementation late in life. J. Clin. Endocrinol. Metab. 2015,100, L49-L50. [CrossRef] [PubMed]
  54. Marzolo, M.P.; Farfan, P. New insights into the roles of megalin/LRP2 and the regulation of its functional expression. Biol. Res. 2011, 44, 89-105. [CrossRef]
  55. Wimalawansa, S. Overcoming infections including COVID-19, by maintaining circulating 25(OH)D concentrations above 50 ng/mL. Pathol. Lab. Med. Int. 2022,14, 37-60. [CrossRef]
  56. Wimalawansa, S.J. Rapidly Increasing Serum 25(OH)D Boosts the Immune System, against Infections-Sepsis and COVID-19. Nutrients 2022,14, 2997. [CrossRef]
  57. Ianevski, A.; Zusinaite, E.; Shtaida, N.; Kallio-Kokko, H.; Valkonen, M.; Kantele, A.; Telling, K.; Lutsar, I.; Letjuka, P.; Metelitsa, N.; et al. Low Temperature and Low UV Indexes Correlated with Peaks of Influenza Virus Activity in Northern Europe during 2010-2018. Viruses 2019,11, 207. [CrossRef]
  58. Imai, C.M.; Halldorsson, T.I.; Eiriksdottir, G.; Cotch, M.F.; Steingrimsdottir, L.; Thorsdottir, I.; Launer, L.J.; Harris, T.; Gudnason, V.; Gunnarsdottir, I. Depression and serum 25-hydroxyvitamin D in older adults living at northern latitudes—AGES-Reykjavik Study. J. Nutr. Sci. 2015, 4, e37. [CrossRef]
  59. Devaraj, S.; Jialal, G.; Cook, T.; Siegel, D.; Jialal, I. Low vitamin D levels in Northern American adults with the metabolic syndrome. Horm. Metab. Res. 2011, 43, 72-74. [CrossRef]
  60. Reichrath, J.; Saternus, R.; Vogt, T. Challenge and perspective: The relevance of ultraviolet (UV) radiation and the vitamin D endocrine system (VDES) for psoriasis and other inflammatory skin diseases. Photochem. Photobiol. Sci. 2017, 16, 433-444. [CrossRef]
  61. Premkumar, M.; Sable, T.; Dhanwal, D.; Dewan, R. Vitamin D homeostasis, bone mineral metabolism, and seasonal affective disorder during 1 year of Antarctic residence. Arch. Osteoporos. 2013, 8,129. [CrossRef] [PubMed]
  62. Saraiva, G.L.; Cendoroglo, M.S.; Ramos, L.R.; Araujo, L.M.; Vieira, J.G.; Kunii, I.; Hayashi, L.F.; Correa, M.P.; Lazaretti-Castro, M. Influence of ultraviolet radiation on the production of 25 hydroxyvitamin D in the elderly population in the city of Sao Paulo (23 degrees 34'S), Brazil. Osteoporos. Int. 2005,16,1649-1654. [CrossRef] [PubMed]
  63. Pletz, M.W.; Terkamp, C.; Schumacher, U.; Rohde, G.; Schutte, H.; Welte, T.; Bals, R.; Group, C.A.-S. Vitamin D deficiency in community-acquired pneumonia: Low levels of 1,25(OH)2 D are associated with disease severity. Respir. Res. 2014, 15, 53. [CrossRef]
  64. Ginde, A.A.; Mansbach, J.M.; Camargo, C.A., Jr. Vitamin D, respiratory infections, and asthma. Curr. Allergy Asthma Rep. 2009, 9, 81-87. [CrossRef] [PubMed]
  65. Czaja, A.J. Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis. World J. Gastroenterol. 2016,22, 9257-9278. [CrossRef]
  66. Jin, D.; Wu, S.; Zhang, Y.G.; Lu, R.; Xia, Y.; Dong, H.; Sun, J. Lack of Vitamin D Receptor Causes Dysbiosis and Changes the Functions of the Murine Intestinal Microbiome. Clin. Ther. 2015, 37, 996-1009 e1007. [CrossRef]
  67. Zhou, Y.F.; Luo, B.A.; Qin, L.L. The association between vitamin D deficiency and community-acquired pneumonia: A meta­analysis of observational studies. Medicine 2019, 98, e17252. [CrossRef]
  68. Laplana, M.; Royo, J.L.L.; Fibla, J. Vitamin D Receptor polymorphisms and risk of enveloped virus infection: A meta-analysis. Gene 2018, 678, 384-394. [CrossRef]
  69. Platitsyna, N.G.; Bolotnova, T.V. Vitamin D deficiency as a risk factor for chronic non-infectious diseases. Adv. Gerontol. 2017, 30, 873-879.
  70. Grant, W.B.; Lahore, H.; McDonnell, S.L.; Baggerly, C.A.; French, C.B.; Aliano, J.L.; Bhattoa, H.P. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients 2020,12,1626. [CrossRef]
  71. Eroglu, C.; Demir, F.; Erge, D.; Uysal, P.; Kirdar, S.; Yilmaz, M.; Kurt Omurlu, I. The relation between serum vitamin D levels, viral infections and severity of attacks in children with recurrent wheezing. Allergol. Immunopathol. (Madr.) 2019, 47, 591-597. [CrossRef]
  72. Arihiro, S.; Nakashima, A.; Matsuoka, M.; Suto, S.; Uchiyama, K.; Kato, T.; Mitobe, J.; Komoike, N.; Itagaki, M.; Miyakawa, Y.; et al. Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza and Upper Respiratory Infection in Patients with Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2019, 25,1088-1095. [CrossRef]
  73. Jolliffe, D.A.; Greiller, C.L.; Mein, C.A.; Hoti, M.; Bakhsoliani, E.; Telcian, A.G.; Simpson, A.; Barnes, N.C.; Curtin, J.A.; Custovic, A.; et al. Vitamin D receptor genotype influences risk of upper respiratory infection. Br. J. Nutr. 2018,120, 891-900. [CrossRef] [PubMed]
  74. Wagner, C.L.; Hollis, B.W.; Kotsa, K.; Fakhoury, H.; Karras, S.N. Vitamin D administration during pregnancy as prevention for pregnancy, neonatal and postnatal complications. Rev. Endocr. Metab. Disord. 2017,18, 307-322. [CrossRef] [PubMed]
  75. Morris, S.K.; Pell, L.G.; Rahman, M.Z.; Dimitris, M.C.; Mahmud, A.; Islam, M.M.; Ahmed, T.; Pullenayegum, E.; Kashem, T.; Shanta, S.S.; et al. Maternal vitamin D supplementation during pregnancy and lactation to prevent acute respiratory infections in infancy in Dhaka, Bangladesh (MDARI trial): Protocol for a prospective cohort study nested within a randomized controlled trial. BMC Pregnancy Childbirth 2016,16, 309. [CrossRef] [PubMed]
  76. Wimalawansa, S.J.; Polonowita, A. Boosting immunity with vitamin D for preventing complications and deaths from COVID-19. In Proceedings of the COVID 19: Impact, Mitigation, Opportunities and Building Resilience "From Adversity to Serendipity", Perspectives of Global Relevance Based on Research, Experience and Successes in Combating COVID-19 in Sri Lanka, Colombo, Sri Lanka, 27-28 January 2021; pp. 171-198.
  77. Kone-Paut, I.; Cimaz, R. Is it Kawasaki shock syndrome, Kawasaki-like disease or pediatric inflammatory multisystem disease? The importance of semantic in the era of COVID-19 pandemic. RMD Open 2020, 6, e001333. [CrossRef]
  78. Pouletty, M.; Borocco, C.; Ouldali, N.; Caseris, M.; Basmaci, R.; Lachaume, N.; Bensaid, P.; Pichard, S.; Kouider, H.; Morelle, G.; et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): A multicentre cohort. Ann. Rheum. Dis. 2020, 79, 999-1006. [CrossRef]
  79. Stagi, S.; Rigante, D.; Lepri, G.; Matucci Cerinic, M.; Falcini, F. Severe vitamin D deficiency in patients with Kawasaki disease: A potential role in the risk to develop heart vascular abnormalities? Clin. Rheumatol. 2016, 35,1865-1872. [CrossRef]
  80. Torpoco Rivera, D.; Misra, A.; Sanil, Y.; Sabzghabaei, N.; Safa, R.; Garcia, R.U. Vitamin D and morbidity in children with Multisystem inflammatory syndrome related to COVID-19. Prog Pediatr Cardiol. 2022, 66, 101507. Available online: https: //www.ncbi.nlm.nih.gov/pubmed/35250251 (accessed on 14 August 2023). [CrossRef]
  81. Oliver, S.M. The immune system and new therapies for inflammatory joint disease. Musculoskelet. Care 2003,1,44-57. [CrossRef]
  82. Wimalawansa, S.J. Global epidemic of coronavirus—COVID-19: What can we do to minimize risks? Eur. J. Biomed. Pharma Sci. 2020, 7, 432-438.
  83. Wimalawansa, S.J.; Razzaque, M.S.; Al-Daghri, N.M. Calcium and vitamin D in human health: Hype or real? J. Steroid Biochem. Mol. Biol. 2018,180, 4-14. [CrossRef]
  84. Soltani-Zangbar, M.S.; Mahmoodpoor, A.; Dolati, S.; Shamekh, A.; Valizadeh, S.; Yousefi, M.; Sanaie, S. Serum levels of vitamin D and immune system function in patients with COVID-19 admitted to intensive care unit. Gene Rep. 2022,26,101509. [CrossRef]
  85. Arora, J.; Wang, J.; Weaver, V.; Zhang, Y.; Cantorna, M.T. Novel insight into the role of the vitamin D receptor in the development and function of the immune system. J. Steroid Biochem. Mol. Biol. 2022, 219,106084. [CrossRef] [PubMed]
  86. Quraishi, S.A.; Bittner, E.A.; Blum, L.; McCarthy, C.M.; Bhan, I.; Camargo, C.A., Jr. Prospective study of vitamin D status at initiation of care in critically ill surgical patients and risk of 90-day mortality. Crit. Care Med. 2014, 42,1365-1371. [CrossRef]
  87. Chauss, D.; Freiwald, T.; McGregor, R.; Yan, B.; Wang, L.; Nova-Lamperti, E.; Kumar, D.; Zhang, Z.; Teague, H.; West, E.E.; et al. Autocrine vitamin D signaling switches off pro-inflammatory programs of T(H)1 cells. Nat. Immunol. 2022, 23, 62-74. [CrossRef] [PubMed]
  88. Sun, L.; Arbesman, J.; Piliang, M. Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors. Arch. Dermatol. Res. 2021, 313,1-10. [CrossRef] [PubMed]
  89. Johnson, C.R.; Thacher, T.D. Vitamin D: Immune function, inflammation, infections and auto-immunity. Paediatr. Int. Child Health 2023,1-11. [CrossRef] [PubMed]
  90. McCartney, D.M.; Byrne, D.G. Optimisation of vitamin D status for enhanced immuno-protection against COVID-19. Ir. Med. J. 2020,113, 58. [PubMed]
  91. Tsujino, I.; Ushikoshi-Nakayama, R.; Yamazaki, T.; Matsumoto, N.; Saito, I. Pulmonary activation of vitamin D(3) and preventive effect against interstitial pneumonia. J. Clin. Biochem. Nutr. 2019, 65, 245-251. [CrossRef]
  92. Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M.; Endocrine, S. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96,1911-1930. [CrossRef] [PubMed]
  93. Anonymus. Vitamin D for COVID-19: Real-Time Analysis of All 300 Studies. Available online: https://c19vitamind.com/ (accessed on 25 January 2023).
  94. Adams, J.S.; Modlin, R.L.; Diz, M.M.M.; Barnes, P.F. Potentiation of the macrophage 25-hydroxyvitamin D-1-hydroxylation reaction by human tuberculous pleural effusion fluid. J. Clin. Endocrinol. Metab. 1989, 69, 457-460. [CrossRef] [PubMed]
  95. Antal, A.S.; Dombrowski, Y.; Koglin, S.; Ruzicka, T.; Schauber, J. Impact of vitamin D3 on cutaneous immunity and antimicrobial peptide expression. Dermatoendocrinology 2011, 3,18-22. [CrossRef] [PubMed]
  96. Ahorsu, D.K.; Imani, V.; Lin, C.Y.; Timpka, T.; Brostrom, A.; Updegraff, J.A.; Arestedt, K.; Griffiths, M.D.; Pakpour, A.H. Associations between Fear of COVID-19, Mental Health, and Preventive Behaviours Across Pregnant Women and Husbands: An Actor-Partner Interdependence Modelling. Int. J. Ment. Health Addict. 2022, 20, 68-82. [CrossRef] [PubMed]
  97. Aloia, J.F.; Li-Ng, M. Re: Epidemic influenza and vitamin D. Epidemiol. Infect. 2007,135,1095-1096. [CrossRef]
  98. Fleming, D.M.; Elliot, A.J. Epidemic influenza and vitamin D. Epidemiol. Infect. 2007,135,1091-1092. [CrossRef]
  99. Ali, M.; Uddin, Z. Factors associated with vitamin D deficiency among patients with musculoskeletal disorders seeking physiotherapy intervention: A hospital-based observational study. BMC Musculoskelet. Disord. 2022, 23, 817. [CrossRef]
  100. Dawodu, A.; Saadi, H.F.F.; Bekdache, G.; Javed, Y.; Altaye, M.; Hollis, B.W. Randomized controlled trial (RCT) of vitamin D supplementation in pregnancy in a population with endemic vitamin D deficiency. J. Clin. Endocrinol. Metab. 2013, 98, 2337-2346. [CrossRef]
  101. Camargo, C.A., Jr.; Ganmaa, D.; Frazier, A.L.; Kirchberg, F.F.; Stuart, J.J.; Kleinman, K.; Sumberzul, N.; Rich-Edwards, J.W. Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia. Pediatrics 2012,130, e561-e567. [CrossRef]
  102. Bergman, P.; Norlin, A.C.; Hansen, S.; Rekha, R.S.; Agerberth, B.; Bjorkhem-Bergman, L.; Ekstrom, L.; Lindh, J.D.; Andersson, J. Vitamin D3 supplementation in patients with frequent respiratory tract infections: A randomised and double-blind intervention study. BMJ Open 2012, 2, e001663. [CrossRef]
  103. Hutchinson, M.S.; Grimnes, G.; Joakimsen, R.M.; Figenschau, Y.; Jorde, R. Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: The Tromso study. Eur. J. Endocrinol. 2010,162,935-942. [CrossRef]
  104. Murdoch, D.R.; Slow, S.; Chambers, S.T.; Jennings, L.C.; Stewart, A.W.; Priest, P.C.; Florkowski, C.M.; Livesey, J.H.; Camargo, C.A.; Scragg, R. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: The VIDARIS randomized controlled trial. JAMA 2012, 308,1333-1339. [CrossRef]
  105. Manaseki-Holland, S.; Maroof, Z.; Bruce, J.; Mughal, M.Z.Z.; Masher, M.I.I.; Bhutta, Z.A.; Walraven, G.; Chandramohan, D. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: A randomised controlled superiority trial. Lancet 2012, 379,1419-1427. [CrossRef] [PubMed]
  106. Martineau, A.R.; Timms, P.M.; Bothamley, G.H.; Hanifa, Y.; Islam, K.; Claxton, A.P.; Packe, G.E.; Moore-Gillon, J.C.; Darmalingam, M.; Davidson, R.N.; et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: A double-blind randomised controlled trial. Lancet 2011, 377, 242-250. [CrossRef] [PubMed]
  107. Ross, A.C.; Manson, J.E.; Abrams, S.A.; Aloia, J.F.; Brannon, P.M.; Clinton, S.K.; Durazo-Arvizu, R.A.; Gallagher, J.C.; Gallo, R.L.; Jones, G.; et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J. Clin. Endocrinol. Metab. 2011, 96, 53-58. [CrossRef] [PubMed]
  108. Kimball, S.; Vieth, R.; Dosch, H.M.; Bar-Or, A.; Cheung, R.; Gagne, D.; O'Connor, P.; D'Souza, C.; Ursell, M.; Burton, J.M. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. J. Clin. Endocrinol. Metab. 2011, 96, 2826-2834. [CrossRef]
  109. Heaney, R.P.; Davies, K.M.; Chen, T.C.; Holick, M.F.; Barger-Lux, M.J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am. J. Clin. Nutr. 2003, 77, 204-210. [CrossRef]
  110. Sanders, K.M.; Stuart, A.L.; Williamson, E.J.; Simpson, J.A.; Kotowicz, M.A.; Young, D.; Nicholson, G.C. Annual high-dose oral vitamin D and falls and fractures in older women: A randomized controlled trial. JAMA 2010, 303,1815-1822. [CrossRef]
  111. Nowson, C.A.; McGrath, J.J.; Ebeling, P.R.; Haikerwal, A.; Daly, R.M.; Sanders, K.M.; Seibel, M.J.; Mason, R.S.; Working Group of Australian and New Zealand Bone and Mineral Society, Endocrine Society of Australia and Osteoporosis Australia. Vitamin D and health in adults in Australia and New Zealand: A position statement. Med. J. Aust. 2012,196, 686-687. [CrossRef]
  112. Schwalfenberg, G.K.; Whiting, S.J. A Canadian response to the 2010 Institute of Medicine vitamin D and calcium guidelines. Public Health Nutr. 2011,14, 746-748. [CrossRef]
  113. Lappe, J.M.; Travers-Gustafson, D.; Davies, K.M.; Recker, R.R.; Heaney, R.P. Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am. J. Clin. Nutr. 2007, 85,1586-1591. [CrossRef]
  114. Marshall, D.T.; Savage, S.J.; Garrett-Mayer, E.; Keane, T.E.; Hollis, B.W.; Horst, R.L.; Ambrose, L.H.; Kindy, M.S.S.; Gattoni-Celli, S. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J. Clin. Endocrinol. Metab. 2012, 97, 2315-2324. [CrossRef] [PubMed]
  115. Forman, J.P.; Scott, J.B.; Ng, K.; Drake, B.F.; Suarez, E.G.; Hayden, D.L.; Bennett, G.G.; Chandler, P.D.; Hollis, B.W.; Emmons, K.M.; et al. Effect of vitamin D supplementation on blood pressure in blacks. Hypertension 2013, 61, 779-785. [CrossRef] [PubMed]
  116. Mitri, J.; Dawson-Hughes, B.; Hu, F.B.; Pittas, A.G. Effects of vitamin D and calcium supplementation on pancreatic beta cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: The Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. Am. J. Clin. Nutr. 2011, 94, 486-494. [CrossRef]
  117. von Hurst, P.R.; Stonehouse, W.; Coad, J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient—A randomised, placebo-controlled trial. Br. J. Nutr. 2010,103, 549-555. [CrossRef]
  118. Belenchia, A.M.; Tosh, A.K.; Hillman, L.S.; Peterson, C.A. Correcting vitamin D insufficiency improves insulin sensitivity in obese adolescents: A randomized controlled trial. Am. J. Clin. Nutr. 2013, 97, 774-781. [CrossRef] [PubMed]
  119. Derakhshandi, H.; Etemadifar, M.; Feizi, A.; Abtahi, S.H.; Minagar, A.; Abtahi, M.A.; Abtahi, Z.A.; Dehghani, A.; Sajjadi, S.; Tabrizi, N. Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: A double blind, randomized, placebo-controlled pilot clinical trial. Acta Neurol. Belg. 2013,113, 257-263. [CrossRef] [PubMed]
  120. Hollis, B.W.; Wagner, C.L. Vitamin D requirements during lactation: High-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant. Am. J. Clin. Nutr. 2004, 80,1752S-1758S. [CrossRef]
  121. Trivedi, D.; Doll, R.; Khaw, K.T. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial. BMJ 2003, 326, 469. [CrossRef]
  122. Johansson, H.; Oden, A.; Kanis, J.; McCloskey, E.; Lorentzon, M.; Ljunggren, O.; Karlsson, M.K.; Thorsby, P.M.; Tivesten, A.; Barrett-Connor, E.; et al. Low serum vitamin D is associated with increased mortality in elderly men: MrOS Sweden. Osteoporos. Int. 2012,23, 991-999. [CrossRef]
  123. Hollis, B.W.; Wagner, C.L. Clinical review: The role of the parent compound vitamin D with respect to metabolism and function: Why clinical dose intervals can affect clinical outcomes. J. Clin. Endocrinol. Metab. 2013, 98, 4619-4628. [CrossRef]
  124. Morris, H.A.; Anderson, P.H. Autocrine and paracrine actions of vitamin d. Clin. Biochem. Rev. 2010, 31,129-138.
  125. Atkinson, R.L. Viruses as an etiology of obesity. Mayo Clin. Proc. 2007, 82,1192-1198. [CrossRef] [PubMed]
  126. McGregor, R.; Chauss, D.; Freiwald, T.; Yan, B.; Wang, L.; Nova-Lamperti, E.; Zhang, Z.; Teague, H.; West, E.E.E.; Bibby, J.; et al. An autocrine Vitamin D-driven Th1 shutdown program can be exploited for COVID-19. bioRxiv 2020. [CrossRef]
  127. Gibson, C.C.; Davis, C.T.; Zhu, W.; Bowman-Kirigin, J.A.; Walker, A.E.; Tai, Z.; Thomas, K.R.; Donato, A.J.; Lesniewski, L.A.; Li, D.Y. Dietary Vitamin D and Its Metabolites Non-Genomically Stabilize the Endothelium. PLoS ONE 2015,10, e0140370. [CrossRef]
  128. Moromizato, T.; Litonjua, A.A.; Braun, A.B.; Gibbons, F.K.; Giovannucci, E.; Christopher, K.B. Association of low serum 25-hydroxyvitamin D levels and sepsis in the critically ill. Crit. Care Med. 2014, 42, 97-107. [CrossRef] [PubMed]
  129. Tolppanen, A.M.; Fraser, A.; Fraser, W.D.; Lawlor, D.A. Risk factors for variation in 25-hydroxyvitamin D(3) and D(2) concentra­tions and vitamin D deficiency in children. J. Clin. Endocrinol. Metab. 2012, 97,1202-1210. [CrossRef]
  130. Bae, J.H.; Choe, H.J.; Holick, M.F.; Lim, S. Association of vitamin D status with COVID-19 and its severity: Vitamin D and COVID-19: A narrative review. Rev. Endocr. Metab. Disord. 2022,23, 579-599. [CrossRef]
  131. Holick, M.F. Sunlight, UV Radiation, Vitamin D, and Skin Cancer: How Much Sunlight Do We Need? Adv. Exp. Med. Biol. 2020,1268,19-36. [CrossRef]
  132. Heaney, R.; Armas, L.; Shary, J.; Bell, N.; Binkley, N.; Hollis, B. 25-Hydroxylation of vitamin D3: Relation to circulating vitamin D3 under various input conditions. Am. J. Clin. Nutr. 2008, 87,1738-1742. [CrossRef]
  133. Hollis, B.W. Short-term and long-term consequences and concerns regarding valid assessment of vitamin D deficiency: Com­parison of recent food supplementation and clinical guidance reports. Curr. Opin. Clin. Nutr. Metab. Care 2011, 14, 598-604. [CrossRef] [PubMed]
  134. Urashima, M.; Segawa, T.; Okazaki, M.; Kurihara, M.; Wada, Y.; Ida, H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am. J. Clin. Nutr. 2010, 91,1255-1260. [CrossRef] [PubMed]
  135. Bergman, P.; Lindh, A.U.; Bjorkhem-Bergman, L.; Lindh, J.D. Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE 2013, 8, e65835. [CrossRef] [PubMed]
  136. Borel, P.; Caillaud, D.; Cano, N.J. Vitamin D bioavailability: State of the art. Crit. Rev. Food Sci. Nutr. 2015, 55, 1193-1205. [CrossRef] [PubMed]
  137. Greer, F.R.; Hollis, B.W.; Napoli, J.L. High concentrations of vitamin D2 in human milk associated with pharmacologic doses of vitamin D2. J. Pediatr. 1984,105, 61-64. [CrossRef]
  138. Greer, F.R.; Hollis, B.W.; Cripps, D.J.; Tsang, R.C. Effects of maternal ultraviolet B irradiation on vitamin D content of human milk. J. Pediatr. 1984,105, 431-433. [CrossRef]
  139. Ziegler, E.E.; Hollis, B.W.; Nelson, S.E.; Jeter, J.M. Vitamin D deficiency in breastfed infants in Iowa. Pediatrics 2006,118, 603-610. [CrossRef]
  140. Wagner, C.L.; Greer, F.R.; American Academy of Pediatrics Section on Breastfeeding; American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008,122,1142-1152. [CrossRef]
  141. Hollis, B.W.; Pittard, W.B., 3rd. Evaluation of the total fetomaternal vitamin D relationships at term: Evidence for racial differences. J. Clin. Endocrinol. Metab. 1984, 59, 652-657. [CrossRef]
  142. Hillman, L.S.; Haddad, J.G. Human perinatal vitamin D metabolism. I. 25-Hydroxyvitamin D in maternal and cord blood. J. Pediatr. 1974, 84, 742-749. [CrossRef]
  143. Heyden, E.L.; Wimalawansa, S.J. Vitamin D: Effects on human reproduction, pregnancy, and fetal well-being. J. Steroid Biochem. Mol. Biol. 2018,180, 41-50. [CrossRef] [PubMed]
  144. Hanel, A.; Bendik, I.; Carlberg, C. Transcriptome-Wide Profile of 25-Hydroxyvitamin D(3) in Primary Immune Cells from Human Peripheral Blood. Nutrients 2021,13, 4100. [CrossRef] [PubMed]
  145. Aygun, H. Vitamin D can prevent COVID-19 infection-induced multiple organ damage. Naunyn Schmiedebergs Arch. Pharmacol. 2020, 393, 1157-1160. [CrossRef] [PubMed]
  146. Wimalawansa, S. Commonsense approaches to minimizing risks from COVID-19. J. Pulmonol. Resp. Med. 2020, 2, 28-37. [CrossRef]
  147. Grant, W.B. Variations in vitamin D production could possibly explain the seasonality of childhood respiratory infections in Hawaii. Pediatr. Infect. Dis. J. 2008, 27, 853. [CrossRef] [PubMed]
  148. Martineau, A.R.; Jolliffe, D.A.; Hooper, R.L.; Greenberg, L.; Aloia, J.F.; Bergman, P.; Dubnov-Raz, G.; Esposito, S.; Ganmaa, D.; Ginde, A.A.; et al. Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data. BMJ 2017, 356, i6583. [CrossRef] [PubMed]
  149. Wimalawansa, S.J. Fighting against COVID-19: Boosting the immunity with micronutrients, stress reduction, physical activity, and vitamin D. Nutr. Food Sci. J. (Sci. Lit.) 2020, 3,126.
  150. Chetty, V.; Chetty, M. Potential benefit of vitamin D supplementation in people with respiratory illnesses, during the COVID-19 pandemic. Clin. Transl. Sci. 2021,14, 2111-2116. [CrossRef]
  151. D'Avolio, A.; Avataneo, V.; Manca, A.; Cusato, J.; De Nicolo, A.; Lucchini, R.; Keller, F.; Cantu, M. 25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. Nutrients 2020,12,1359. [CrossRef]
  152. Kaufman, H.W.; Niles, J.K.; Kroll, M.H.; Bi, C.; Holick, M.F. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. PLoS ONE 2020,15, e0239252. [CrossRef]
  153. DiNicolantonio, J.; O'Keefe, J. Magnesium and vitamin D deficiency as a potential cause of immune dysfunction, cytokine storm and disseminated intravascular coagulation in covid-19 patients. Mol. Med. 2021,118, 68-73.
  154. Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; McGinn, T.; Davidson, K.W.; the Northwell, C.-R.C.; Barnaby, D.P.; Becker, L.B.; Chelico, J.D.; et al. Presenting Characteristics, Co-morbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA 2020, 323, 2052-2059. [CrossRef]
  155. Kurylowicz, A.; Bednarczuk, T.; Nauman, J. The influence of vitamin D deficiency on cancers and autoimmune diseases development. Endokrynol. Pol. 2007, 58,140-152.
  156. Quraishi, S.A.; Bittner, E.A.; Blum, L.; Hutter, M.M.; Camargo, C.A., Jr. Association between preoperative 25-hydroxyvitamin D level and hospital-acquired infections following Roux-en-Y gastric bypass surgery. JAMA Surg. 2014,149,112-118. [CrossRef] [PubMed]
  157. Quraishi, S.A.; De Pascale, G.; Needleman, J.S.; Nakazawa, H.; Kaneki, M.; Bajwa, E.K.; Camargo, C.A., Jr.; Bhan, I. Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis: A Randomized, Placebo-Controlled Trial. Crit. Care Med. 2015, 43,1928-1937. [CrossRef] [PubMed]
  158. Borsche, L.; Glauner, B.; von Mendel, J. COVID-19 Mortality Risk Correlates Inversely with Vitamin D3 Status, and a Mortality Rate Close to Zero Could Theoretically Be Achieved at 50 ng/mL 25(OH)D3: Results of a Systematic Review and Meta-Analysis. Nutrients 2021,13, 3596. [CrossRef] [PubMed]
  159. Shrestha, N.K.; Shrestha, P.; Burke, P.C.; Nowacki, A.S.; Terpeluk, P.; Gordon, S.M. Coronavirus Disease 2019 Vaccine Boosting in Previously Infected or Vaccinated Individuals. Clin. Infect. Dis. 2022, 75, 2169-2177. [CrossRef]
  160. Uraki, R.; Ito, M.; Furusawa, Y.; Yamayoshi, S.; Iwatsuki-Horimoto, K.; Adachi, E.; Saito, M.; Koga, M.; Tsutsumi, T.; Yamamoto, S.; et al. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect. Dis. 2023, 23, 30-32. [CrossRef]
  161. Dingemans, J.; van der Veer, B.; Gorgels, K.M.F.; Hackert, V.; den Heijer, C.D.J.; Hoebe, C.; Savelkoul, P.H.M.; van Alphen, L.B. Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type. Front. Microbiol. 2022,13,1027271. [CrossRef]
  162. Wimalawansa, S.J. Controlling COVID-19 pandemic with cholecalciferol. World J. Adv. Heathc. Res. 2020, 5,155-165. [CrossRef]
  163. Arabi, Y.M.M.; Fowler, R.; Hayden, F.G. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med. 2020, 46, 315-328. [CrossRef]
  164. Wimalawansa, S.J. Effective and practical ways to overcome vitamin D deficiency. J. Family Med. Community Health 2021, 8,1185.
  165. Aslam, S.; Danziger-Isakov, L.; Mehra, M.R. COVID-19 vaccination immune paresis in heart and lung transplantation. J. Heart Lung Transplant. 2021, 40, 763-766. [CrossRef] [PubMed]
  166. Biesalski, H.K.; Aggett, P.J.; Anton, R.; Bernstein, P.S.; Blumberg, J.; Heaney, R.P.; Henry, J.; Nolan, J.M.; Richardson, D.P.; van Ommen, B.; et al. 26th Hohenheim Consensus Conference, September 11, 2010 Scientific substantiation of health claims: Evidence-based nutrition. Nutrition 2011, 27, S1-S20. [CrossRef]
  167. Tsai, F.; Coyle, W.J. The microbiome and obesity: Is obesity linked to our gut flora? Curr. Gastroenterol. Rep. 2009,11, 307-313. [CrossRef]
  168. Dai, Q.; Zhu, X.; Manson, J.E.; Song, Y.; Li, X.; Franke, A.A.; Costello, R.B.; Rosanoff, A.; Nian, H.; Fan, L.; et al. Magnesium status and supplementation influence vitamin D status and metabolism: Results from a randomized trial. Am. J. Clin. Nutr. 2018,108, 1249-1258. [CrossRef]
FLCCC: Understanding Vitamin D video by Drs. Sunil Wimalawansa and Paul Marik - Aug 2023

80 minute video starts at 5 minutes

FLCCC EARLY COVID TREATMENT consists of many things, such as vitamin D

FLCCC = Front Line COVID-19 Critical Care Alliance
Table 3. A Single-Dose Regimen of Calcifediol to Rapidly Raise Serum 25(OH)D above 50 ng/mL

Body Weight
  (lbs)		Body Weight
  (kgs)		Calcifediol
  (mg)		Equivalent
in IU		If Calcifediol is not available
a bolus of Vitamin D3
15-217-100.116,00020,000
22-3010-140.1524,00035,000
31-4015-180.232,00050,000
41-5019-230.348,00060,000
61-7028-320.580,000100,000
71-8633-390.696,000150,000
86-10040-450.7112,000200,000
101-15046-680.8128,000250,000
151-20069-901.0160,000300,000
201-30091-1361.15240,000400,000
>300>1372.0320,000500,000

40-150 ng of Vitamin D is needed to treat health problems

Vitamin D Treats
150 ng Multiple Sclerosis *
80 ng Cluster Headache *
Reduced office visits by 4X *
70 ngSleep *
60 ngBreast Cancer death reduced 60%
Preeclampsia RCT
50 ng COVID-19
T1 Diabetes
Fertility
Psoriasis
Infections Review
Infection after surgery
40 ng Breast Cancer 65% lower risk
Depression
ACL recovery
Hypertension
Asthma?
30 ng Rickets

* Evolution of experiments with patients, often also need co-factors

VitaminDwiki - Prevent a COVID death: 9 dollars of Vitamin D or 900,000 dollars of vaccine - Aug 2023

Many Chronic Health Diseases and Infections can controlled by 40 ng of Vitamin D – Aug 2023        
3448 visitors, last modified 18 Aug, 2023,
(Cached) Printer Friendly Follow this page for updates
Page actions
Refresh Print
Edit Files 5

Attached files

ID Name Comment Uploaded Size Downloads
19971 Benefits.jpg admin 18 Aug, 2023 223.54 Kb 155
19970 Pathways.jpg admin 18 Aug, 2023 170.90 Kb 181
19969 Summary.jpg admin 18 Aug, 2023 90.01 Kb 326
19968 ToC Sunil.jpg admin 18 Aug, 2023 46.63 Kb 156
19967 Sunil chronic_CompressPdf.pdf admin 18 Aug, 2023 732.20 Kb 127